Medicare Coverage For Alzheimer’s Treatments Should Have Flexibilities For Labeling Differences, Developers say

Lilly and Genentech express concern that the Centers for Medicare and Medicaid Services will set Medicare coverage parameters for their Alzheimer’s drugs even before all the data is in.

Drug industry comments respond to Medicare national coverage analysis. • Source: Alamy

More from Market Access

More from Pink Sheet